This post was originally published on this site The European Commission (EC) has expanded the use of Imbruvica (ibrutinib) to cover combinations with Gazyva (obinutuzumab) for previously untreated adults with chronic lymphocytic leukemia (CLL), and with MabThera (rituximab) for adults with Waldenström’s macroglobulinemia (WM). This decision follows a recent positive opinion from the European Medicines Agency’s…
This post was originally published on this site Cancer has a way of isolating us. Friends and family can be supportive, but sometimes they don’t understand what you’re going through. I have found that it helps to think of myself as one part of a larger community. In my 11-plus years as a follicular lymphoma…
This post was originally published on this site ADXS-NEO, an investigational cancer immunotherapy, induced an immune response against 90% of all cancer targets in a patient with metastatic microsatellite stable colorectal cancer (MSS-CRC), data from an ongoing Phase 1 trial show. ADXS-NEO, jointly developed by Advaxis and Amgen, is a new type of personalized cancer…
This post was originally published on this site Immunotep has completed patient enrollment for its Phase 2b trial evaluating eftilagimod alpha (IMP321) — an investigational therapy that stimulates the immune system to fight cancer — in combination with standard chemotherapy for women with hormone receptor (HR)-positive and HER2-negative advanced breast cancer. Combining active immunotherapy with…
This post was originally published on this site Progenics Pharmaceuticals has entered a collaboration with Veteran Affairs Greater Los Angeles Healthcare System (VAGLAHS) to support the development of new machine learning tools aimed at improving detection of prostate cancer through medical imaging. The project is the first collaborative effort in the U.S. to explore pioneering…
This post was originally published on this site Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The open-label trial (NCT03907527), which is still recruiting patients, will be carried out in collaboration with the University of…
This post was originally published on this site Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM), combining this therapy with dexamethasone could be effective if the patients respond partially after the first treatment cycle, according to new research. The study, “Response to First Cycle Is…
This post was originally published on this site Adding Tecentriq (atezolizumab) to standard chemotherapy reduced the risk of disease worsening or death in previously untreated patients with locally advanced or metastatic urothelial cancer, according to early results of a Phase 3 trial Also, according to Genentech — the company marketing Tecentriq — the analysis showed encouraging…
This post was originally published on this site Eagle Pharmaceuticals is preparing a pilot study that may pave the way for a pivotal clinical trial evaluating its new formulation of fulvestrant as a treatment for estrogen receptor (ER)-positive breast cancer. The company believes its new formulation will block estrogen receptors more effectively than AstraZeneca‘s original formulation, approved…
This post was originally published on this site A new statistical analysis of Finland’s nationwide cardiac sarcoidosis (CS) registry found that sudden cardiac death plays a significant role in the outcome of CS patients, affirming the importance of risk assessment in this patient population. The study, “Sudden death in cardiac sarcoidosis: an analysis of nationwide…
